Modality
ASO
MOA
ALKi
Target
KRASG12D
Pathway
Wnt
Hemophilia ADLBCLCLL
Development Pipeline
Preclinical
~Mar 2020
→ ~Jun 2021
Phase 1
~Sep 2021
→ ~Dec 2022
Phase 2
~Mar 2023
→ ~Jun 2024
Phase 3
Sep 2024
→ Mar 2031
Phase 3Current
NCT05262818
2,320 pts·DLBCL
2024-09→2031-03·Not yet recruiting
2,320 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-03-124.9y awayPh3 Readout· DLBCL
Trial Timeline
Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2
P3
Not yet…
Catalysts
Ph3 Readout
2031-03-12 · 4.9y away
DLBCL
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05262818 | Phase 3 | DLBCL | Not yet recr... | 2320 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| MRK-7739 | Merck & Co | Preclinical | IL-23 | |
| SNY-2934 | Sanofi | Phase 3 | KRASG12D | |
| Talainavolisib | Novo Nordisk | Preclinical | KRASG12D | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 | |
| Sovacapivasertib | Amgen | Phase 3 | WEE1 | |
| Zanuratamab | Gilead Sciences | Phase 1/2 | CDK2 | |
| GIL-2445 | Gilead Sciences | Phase 2/3 | PSMA | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D |